Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fluticasone Spiromax
- Development stage
- Phase 2
- Lead developer
- Teva Pharmaceutical Industries
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
Fluticasone Spiromax is an investigational inhaled corticosteroid (ICS) formulation developed by Teva, consisting of fluticasone propionate delivered via the proprietary Spiromax breath-actuated multi-dose dry powder inhaler (DPI). Fluticasone propionate is a synthetic glucocorticoid that acts as a potent agonist at the glucocorticoid receptor, exerting anti-inflammatory effects in the airway to manage asthma symptoms. This specific formulation was evaluated in Phase 2 clinical trials for adolescents and adults with severe persistent asthma that remained uncontrolled on high-dose ICS. The Spiromax device is designed to provide consistent dosing and ease of use, potentially improving adherence and outcomes in patients with severe respiratory disease. While fluticasone propionate is a well-established therapeutic agent, Fluticasone Spiromax was studied as a standalone product in a dose-ranging trial and has not yet received regulatory approval as a monotherapy in this specific delivery system.
- Brand names
- Fluticasone Spiromax
- Other names
- fluticasone propionate Spiromax
02
Targets
AR (Adrenergic receptors)ER (Estrogen receptor)GR (Glucocorticoid receptor)MR (Mineralocorticoid receptor)PR (Progesterone receptor)
Beyond the preview
Go deeper on Fluticasone Spiromax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fluticasone Spiromax.